Comparing PainReform (NASDAQ:PRFX) & Larimar Therapeutics (NASDAQ:LRMR)

PainReform (NASDAQ:PRFX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for PainReform and Larimar Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Larimar Therapeutics	1	0	6	3	3.10

Larimar Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 318.78%. Given Larimar Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than PainReform.

Volatility & Risk

PainReform has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Profitability

This table compares PainReform and Larimar Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Larimar Therapeutics	N/A	-137.70%	-101.43%

Institutional and Insider Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares PainReform and Larimar Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	37.80	-$5.02 million	($736.66)	0.00
Larimar Therapeutics	N/A	N/A	-$165.67 million	($2.21)	-1.78

PainReform has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Summary

Larimar Therapeutics beats PainReform on 7 of the 13 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.